AR070882A1 - 1, 3 -tiazoles sustituidos como inhibidores de mmp-2 y/o mmp-9. - Google Patents

1, 3 -tiazoles sustituidos como inhibidores de mmp-2 y/o mmp-9.

Info

Publication number
AR070882A1
AR070882A1 ARP090100897A ARP090100897A AR070882A1 AR 070882 A1 AR070882 A1 AR 070882A1 AR P090100897 A ARP090100897 A AR P090100897A AR P090100897 A ARP090100897 A AR P090100897A AR 070882 A1 AR070882 A1 AR 070882A1
Authority
AR
Argentina
Prior art keywords
mmp
tiazoles
inhibitors
replaced
group
Prior art date
Application number
ARP090100897A
Other languages
English (en)
Inventor
Shinya Minatoguchi
Yasushi Ohno
Kounori Kotosai
Youichi Yabuuchi
Hisashi Nagamoto
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR070882A1 publication Critical patent/AR070882A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)

Abstract

Una preparacion farmacéutica altamente segura que es eficaz para enfermedades causadas por MMP-2 y/o MMP-9. La preparacion farmacéutica contiene, como ingrediente activo, al menos un miembro seleccionado entre el grupo compuesto por derivados de tiazol representados por la formula (1), en la cual R1 representa un grupo fenilo que puede tener entre 1 y 3 grupos alcoxi inferior como sustituyentes en el anillo de fenilo, y R2 representa un grupo piridilo que puede tener entre 1 y 3 grupos carboxilo como sustituyentes en el anillo de piridina y sus sales. Dichos derivados de tiazol poseen actividad inhibitoria de MMP-2 y/o MMP-9.
ARP090100897A 2008-03-14 2009-03-13 1, 3 -tiazoles sustituidos como inhibidores de mmp-2 y/o mmp-9. AR070882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008065455 2008-03-14

Publications (1)

Publication Number Publication Date
AR070882A1 true AR070882A1 (es) 2010-05-12

Family

ID=40613081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100897A AR070882A1 (es) 2008-03-14 2009-03-13 1, 3 -tiazoles sustituidos como inhibidores de mmp-2 y/o mmp-9.

Country Status (18)

Country Link
US (1) US20110054179A1 (es)
EP (1) EP2280708A1 (es)
JP (2) JP2011513203A (es)
KR (1) KR20100135255A (es)
CN (3) CN101969949B (es)
AR (1) AR070882A1 (es)
AU (1) AU2009224209B2 (es)
BR (1) BRPI0909288A2 (es)
CA (1) CA2718005A1 (es)
IL (2) IL207816A0 (es)
MX (1) MX2010010073A (es)
NZ (1) NZ587591A (es)
RU (1) RU2487131C2 (es)
SG (1) SG188852A1 (es)
TW (1) TWI436767B (es)
UA (1) UA108979C2 (es)
WO (1) WO2009113736A1 (es)
ZA (1) ZA201005991B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617726A4 (en) * 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
EP3837256B1 (en) 2018-08-17 2023-03-08 Novartis AG Urea compounds and compositions as smarca2/brm-atpase inhibitors
AU2023244347A1 (en) * 2022-03-29 2024-10-03 The Trustees Of The University Of Pennsylvania Methods of treating, ameliorating and/or preventing fibrodysplasia ossificans progressiva and heterotopic ossification, and kits for the same
WO2023204170A1 (ja) * 2022-04-18 2023-10-26 大正製薬株式会社 Ｍｍｐ２阻害作用を有する化合物を有効成分として含有する肺の炎症及び線維症の予防又は治療薬

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA962269A (en) * 1971-05-05 1975-02-04 Uniroyal Ltd. Thiazoles, and their use as insecticides
US5639770A (en) * 1992-05-29 1997-06-17 Otsuka Pharmaceutical Co., Ltd. Thiazole derivatives
JP3622015B2 (ja) * 1992-10-08 2005-02-23 敏一 中村 肺傷害治療剤
MY128323A (en) * 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
AU2001238288A1 (en) * 2000-02-16 2001-08-27 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
WO2002046186A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
JP3713577B2 (ja) * 2001-07-24 2005-11-09 大塚製薬株式会社 慢性閉塞性肺疾患治療薬
DK1411936T3 (da) * 2001-07-24 2005-12-27 Otsuka Pharma Co Ltd Anvendelse af thiazolderivater i fremstillingen af et medikament til behandling af kronisk obstruktiv lungesygdom
KR20040081182A (ko) * 2002-02-05 2004-09-20 다이닛본 세이야꾸 가부시끼가이샤 엘라스타제-저해 활성을 가진 이종고리 화합물 및 그 중간체
GB0217504D0 (en) * 2002-07-29 2002-09-04 Novartis Ag Organic compounds
BR0313755A (pt) * 2002-08-23 2005-06-21 Rigel Pharmaceuticals Inc Composto, métodos para inibir a replicação ou proliferação de um vìrion da hepatite c e para tratar ou prevenir uma infecção por hcv, e, composição
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006008119A1 (en) * 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases
JP5846711B2 (ja) * 2005-06-09 2016-01-20 メダ アーベー 炎症性疾患の治療のための方法及び組成物
US20070254913A1 (en) * 2006-04-19 2007-11-01 Dunn Robert F Phosphodiesterase 4 inhibitors
TWI436761B (zh) * 2006-06-19 2014-05-11 Otsuka Pharma Co Ltd 使用噻唑衍生物之方法
ES2378281T3 (es) * 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias

Also Published As

Publication number Publication date
BRPI0909288A2 (pt) 2015-08-18
RU2487131C2 (ru) 2013-07-10
ZA201005991B (en) 2011-10-26
KR20100135255A (ko) 2010-12-24
RU2010141996A (ru) 2012-04-20
CN103622962A (zh) 2014-03-12
TWI436767B (zh) 2014-05-11
TW200942237A (en) 2009-10-16
NZ587591A (en) 2012-10-26
IL228484A0 (en) 2013-12-31
CN101969949A (zh) 2011-02-09
CA2718005A1 (en) 2009-09-17
US20110054179A1 (en) 2011-03-03
WO2009113736A1 (en) 2009-09-17
JP2014221839A (ja) 2014-11-27
EP2280708A1 (en) 2011-02-09
CN103463084A (zh) 2013-12-25
AU2009224209B2 (en) 2015-01-22
MX2010010073A (es) 2010-10-04
UA108979C2 (uk) 2015-07-10
CN101969949B (zh) 2013-12-25
IL207816A0 (en) 2010-12-30
SG188852A1 (en) 2013-04-30
JP2011513203A (ja) 2011-04-28
AU2009224209A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
MX2020000261A (es) Nuevos compuestos.
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
UY29322A1 (es) Inhibidores de cxcr2
AR055116A1 (es) Compuestos aromaticos como agentes terapeuticos para diabetes y composiciones farmaceuticas que los contienen.
CR9580A (es) Inhibidores de la actividad akt
UY30118A1 (es) Compueto amina trisustituido
AR066972A1 (es) Derivados azapeptidicos
UY30835A1 (es) 8-alquinilxantinas y derivados
NZ598750A (en) Therapeutic agent for mood disorders
MX2011010415A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
MX2024005187A (es) Nuevo compuesto espiro.
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
GT200600366A (es) Compuestos de imidazol sustituido como inhibidores de ksp
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες
MX2010010073A (es) Inhibidor de la metaloproteasa de matriz-2 y/o de la metaloproteasa de matriz-9.
NO20033130L (no) Anvendelse av 2-amino-4-heteroaryletyl-tiazolin som inhibitorer av induktibel NO-syntase
CO6290762A2 (es) Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral

Legal Events

Date Code Title Description
FB Suspension of granting procedure